uniQure (QURE) Liabilities and Shareholders Equity (2015 - 2026)
uniQure (QURE) recorded quarterly Liabilities and Shareholders Equity of $778.7 million in Q1 2026, down 5.6% quarter-over-quarter from $824.9 million in Q4 2025, and up 28.63% on a YoY basis from $605.4 million in Q1 2025.
uniQure (QURE) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
uniQure's Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $778.7 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 28.63% year-over-year to $778.7 million; the TTM figure through Mar 2026 stood at $3.1 billion (up 21.2% YoY), while the FY2025 annual figure was $824.9 million, up 48.22% from the prior year.
- Liabilities and Shareholders Equity was $778.7 million for Q1 2026 at uniQure, down from $824.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $942.8 million in Q2 2023 to a low of $556.5 million in Q4 2024.
- Historically, Liabilities and Shareholders Equity has averaged $733.2 million across 5 years, with a median of $730.8 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 108.09% in 2022, then plunged 33.08% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $705.0 million in 2022, then increased by 17.98% to $831.7 million in 2023, then slumped by 33.08% to $556.5 million in 2024, then soared by 48.22% to $824.9 million in 2025, then retreated by 5.6% to $778.7 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $778.7 million (Q1 2026), $824.9 million (Q4 2025), and $888.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn | 778.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 778.71 Mn |
| Dec 31, 2025 | 824.91 Mn |
| Sep 30, 2025 | 888.38 Mn |
| Jun 30, 2025 | 584.89 Mn |
| Mar 31, 2025 | 605.40 Mn |
| Dec 31, 2024 | 556.54 Mn |
| Sep 30, 2024 | 645.81 Mn |
| Jun 30, 2024 | 730.85 Mn |
| Mar 31, 2024 | 770.05 Mn |
| Dec 31, 2023 | 831.69 Mn |
| Sep 30, 2023 | 871.55 Mn |
| Jun 30, 2023 | 942.77 Mn |
| Mar 31, 2023 | 631.00 Mn |
| Dec 31, 2022 | 704.96 Mn |
| Sep 30, 2022 | 638.23 Mn |
| Jun 30, 2022 | 701.21 Mn |
| Mar 31, 2022 | 757.15 Mn |
| Dec 31, 2021 | 809.18 Mn |
| Sep 30, 2021 | 774.63 Mn |
| Jun 30, 2021 | 784.26 Mn |